| Previous Close | 0.3900 |
| Open | 0.3900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3900 - 0.3900 |
| 52 Week Range | 0.1590 - 0.7150 |
| Volume | 6,000 |
| Avg. Volume | 251 |
| Market Cap | 12.307M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0870 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
IIROC Trading Halt - PILL
VANCOUVER, BC, Sept. 17, 2020 /CNW/ - The following issues have been halted by IIROC:Company: Canntab Therapeutics LimitedCSE Symbol: PILL All Issues: YesReason: At the request of the Company Pending NewsHalt Time (ET): 9:34 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.
- CNW Group
Canntab announces planned purchases of cannabis processing equipment and leasehold improvements
TORONTO, Aug. 21, 2020 /CNW/ -Â Canntab Therapeutics Limited (CSE: PILL.
CNW GroupCanntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
TORONTO, June 2, 2020 /CNW/ -Â Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS.TO - News)(OTCQX:MEDIF - News)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products. Orders under the agreement will be composed of a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.
